Research News

 

This resource on Type 1 Diabetes Research was created in partnership with JDRF through the JDRF – Beyond Type 1 Alliance.


 

JDRF Announces Updated Strategy, Renewed Focus in Light of COVID-19


Amidst COVID-19, JDRF prioritizing work in their portfolio that they see as having the highest likelihood for cures and life changing advances for diabetes.MORE

Omnipod Closed Loop Technology to be Compatible with both Abbott and Dexcom CGMs


Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. MORE

New Evidence Shows Vital Importance of Screening For T1D in Children


By screening for Type 1 diabetes in children, Bavaria was able to decrease rates of diabetic ketoacidosis at diagnosis.MORE

vTv Therapeutics Announces Positive Study Results of Potential First-in-Class Oral Adjunctive Therapy for T1D


On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.MORE

JDRF CEO to Health Insurers: Cover New Technology


JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technologyMORE

Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA


The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working togeth...MORE

Implanted PEC-01 Cells Capable of Producing Insulin According to New Data Presented from ViaCyte


ViaCyte presented preliminary data from their PEC-Direct trial, showing that PEC-01 cells are capable of producing insulin in patients with Type 1 diabetes.MORE

JDRF Launches Center of Excellence to Accelerate Cure for Type 1 Diabetes


On September 4, JDRF announced the launch of its Northern California Center of Excellence, dedicated to focused efforts on research and breakthroughs to cure Type 1 diabetes.MORE

Preventing Type 1 Diabetes: Results From TrialNet’s Landmark Teplizumab Trial


The immunotherapy drug teplizumab was shown to delay Type 1 diabetes diagnosis a median of 2 years in children and adults at high risk.MORE

Nonprofits Announce Groundbreaking Research Initiative


The Parker Institute, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced a research initiative to study immunotherapy-induced diabetes. MORE

FDA Approves New Treatment for Diabetic Retinopathy


Regeneron Pharmaceuticals announced that the FDA has approved EYLEA (aflibercept) to treat all stages of diabetic retinopathy.MORE

 


To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.